Loading
Everything OnCo dates to 2006: 147 entries, 42 landmarks, 33 papers listed on people's pages, 24 papers and 15 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
147 dated entries in OnCo fall in 2006: 42 landmarks, 33 papers listed on people's pages, 24 papers, 15 approvals, 9 companies founded, 6 technologies, 6 trials reported, 5 journals founded, 4 regulatory events and 3 laws and regulations.
Of those, 3 to the day, 1 to the month and 143 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC
Head and neck squamous cell carcinoma with radiation
Relapsed or refractory ALL in children after at least two prior regimens (Evoltra)
CML and Ph+ ALL resistant or intolerant to imatinib
Myelodysplastic syndromes, all FAB subtypes and IPSS intermediate-1 to high risk
Ovarian cancer with carboplatin
Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later
Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by...
Replacement therapy in hypogammaglobulinaemia with recurrent bacterial infections in CLL (after failed antibiotic prophylaxis) and plateau-phase multiple myeloma (after failed pneu...
Relapsed myeloma with dexamethasone
EGFR-expressing mCRC after chemotherapy (later RAS wild-type)
Advanced RCC; GIST after imatinib
Newly diagnosed multiple myeloma with dexamethasone
Adjuvant HER2+ breast cancer
Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies
The regulatory events on treatment records: designations, filings, decisions, label changes and withdrawals, most of them carrying a full date.
Original quadrivalent Gardasil approved
Myeloma with dexamethasone
Accelerated approval, refractory mCRC
Adjuvant HER2+ early breast cancer (HERA, NSABP B-31/N9831)
The statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made.
European Union, regulation.
United States, guidance.
European Union, regulation.
The year reported on trial records, with the headline result the record gives.
At twelve months, lymphoedema 5 against 13 percent (relative risk 0.37) and sensory loss 11 against 31 percent (relative risk 0.37) after sentinel node biopsy against standard axil...
Median survival 65.7 against 43.7 months (hazard ratio 0.80); five-year overall survival improved by 8.6 percent.
Median overall survival 49.0 vs 29.3 months (hazard ratio 0.74).
Median survival 7.5 against 8.0 months (p=0.42); twelve-month brain recurrence 46.8 percent with whole-brain radiotherapy against 76.4 percent without.
Magnetic resonance imaging predicted a clear circumferential resection margin correctly in 327 of 349 patients (94 percent), with 92 percent specificity, reproducibly across 11 uni...
Leukaemia-free survival improved over observation in the full population (n=320, P<.01); in first complete remission, 3-year leukaemia-free survival 40% with histamine plus interle...
The publication year on key paper records.
Ezzo JM, Richardson MA, Vickers A, et al. The Cochrane database of systematic reviews.
Bao S, Wu Q, McLendon RE, et al. Nature.
Merlo LM, Pepper JW, Reid BJ, et al. Nature Reviews Cancer.
Beller U, Benedet JL, Creasman WT, et al. International Journal of Gynecology & Obstetrics.
Oeffinger KC, Mertens AC, Sklar CA, et al. New England Journal of Medicine.
Weisenberger DJ, Siegmund KD, Campan M, et al. Nature Genetics.
Sakamoto J, Morita S, Oba K, et al. Cancer immunology, immunotherapy.
Doronina SO, Mendelsohn BA, Bovee TD, et al. Bioconjugate chemistry.
Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. European Urology.
Stummer W, Pichlmeier U, Meinel T, et al. The Lancet Oncology.
Galon J, Costes A, Sanchez-Cabo F, et al. Science.
Huang XJ, Liu DH, Liu KY, et al. Bone marrow transplantation.
Brune M, Castaigne S, Catalano J, et al. Blood.
Calin GA, Croce CM. Nature Reviews Cancer.
Sandler A, Gray R, Perry MC, et al. New England Journal of Medicine.
Roa I, de Aretxabala X, Araya JC, Roa J. Journal of Surgical Oncology.
Carey LA, Perou CM, Livasy CA, et al. JAMA.
Bonner JA, Harari PM, Giralt J, et al. New England Journal of Medicine.
Widdison WC, Wilhelm SD, Cavanagh EE, et al. Journal of medicinal chemistry.
Curtin JA, Busam K, Pinkel D, et al. Journal of Clinical Oncology.
Demetri GD, van Oosterom AT, Garrett CR, et al. The Lancet.
Laurie SA, Licitra L. Journal of Clinical Oncology.
Feinberg AP, Ohlsson R, Henikoff S. Nature reviews. Genetics.
Keall PJ, Mageras GS, Balter JM, et al. Medical physics.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)
Adolescent and young adult cancers (ages 15 to 39)
Chordoma. Vujovic and colleagues show near-universal nuclear brachyury expression.
Triple-negative breast cancer (TNBC). Carey and colleagues, 496 cases; 16 percent in other women.
Head and neck squamous cell carcinoma. First targeted agent in HNSCC.
Head and neck squamous cell carcinoma
Recurrent or metastatic head and neck squamous cell carcinoma
Hypopharyngeal cancer
HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)
Gallbladder cancer. The GES programme, the world's only national prophylactic cholecystectomy policy against gallbladder cancer; 284,139 notifications by 2024.
Colorectal cancer. 195 methylation markers across 295 tumours: CIMP-positive tumours are a distinct subset encompassing almost all BRAF-mutant cancers (odds ratio 203), and are whe...
Tenosynovial giant cell tumour (TGCT). West and colleagues show a CSF1-expressing neoplastic minority recruits the macrophage majority (PNAS).
Mucosal melanoma
Chronic myeloid leukaemia, chronic phase
Inflammatory breast cancer
Cervical cancer
WNT-activated medulloblastoma
Cervical cancer
Vaginal cancer. Protects against the HPV types that cause most vaginal, cervical and vulvar cancers.
Vaginal squamous cell carcinoma (HPV-associated)
Dermatofibrosarcoma protuberans
Multiple myeloma
Oesophageal cancer
Gastric & gastro-oesophageal junction cancer
Borderline resectable pancreatic ductal adenocarcinoma
Lung cancer (all types). ECOG 4599 added bevacizumab to chemotherapy in 878 patients with non-squamous disease: 12.3 against 10.3 months, with a risk of increased treatment-related...
Colorectal cancer. In 408 patients across 11 European units, high-resolution pelvic magnetic resonance imaging predicted a clear circumferential margin with 92 percent specificity...
Pancreatic ductal adenocarcinoma. Vessel contact on CT starts to decide who has surgery first and who has treatment first; the definition was revised yearly until the 2017 internat...
Adolescent and young adult cancers (ages 15 to 39)
Paget disease of the nipple
Anal high-grade squamous intraepithelial lesions (precursor)
Early hepatocellular carcinoma (BCLC 0 and A)
Medulloblastoma
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted
Chronic myeloid leukaemia (CML). Dasatinib (2006) and nilotinib (2007) approved for resistance; later first line (DASISION, ENESTnd).
Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors
Gastrointestinal stromal tumour (GIST)
Imatinib-resistant GIST
Renal cell carcinoma
Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma
Newly diagnosed multiple myeloma, transplant-ineligible
Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)
The since year on technology records: first use in humans or first approval, as the record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
First use in humans or first approval, as the technology record states it.
The founded year on company records.
Emeryville, California
Portland, OR
Stafford, Texas
Caesarea
Maidstone, Kent
San Francisco
Geneva
Austin, TX
San Diego, CA
The founded year on journal records.
Springer
Elsevier
BMC (Springer Nature)
Bentham Science Publishers
Springer Nature (Adis)
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
Cancer Research
American Journal of Respiratory and Critical Care Medicine
Psychiatry Clin Neurosci
Science
Journal of Experimental Medicine
Blood
Critical Care Medicine
Radiology
The Lancet Oncology
Emergency Medicine Journal
Lancet
Revista Española de Geriatría y Gerontología
JCO
J Clin Oncol
New England Journal of Medicine
Plastic & Reconstructive Surgery
Nature
Cancer Res
Cell
Cancer Research
Cell Cycle
Breast Cancer Research
The Oncologist
European Journal of Cancer
Annual Review of Medicine
NEJM
Journal of Clinical Oncology
Nature
Lancet Oncology
Cancer Lett
Pediatric Blood & Cancer
Tropical Doctor
Journal of Clinical Oncology